Clinical trial
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive…
NCT00194714 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00194714 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab |
| Official title | Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo |
| Lead sponsor | University of Washington, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HER2/Neu Positive, HLA-A2 Positive Cells Present, Stage IV Breast Cancer, Stage IV Ovarian Cancer |
| Intervention type | Biological, Other |
| Interventions | HER-2/neu Peptide Vaccine, Laboratory Biomarker Analysis |
| Enrollment | 22 |
| Start date | May 1, 2016 |
| Primary completion | Mar 31, 2021 |
| Completion | May 22, 2023 |
| First posted | Sep 19, 2005 |
| Last update posted | Jun 6, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: